Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR01479
|
|||||
| Drug Name |
Debrisoquine
|
|||||
| Synonyms |
Debrisochinum; Debrisoquina; Debrisoquine; Debrisoquinum; Declinax; Equitonil; Isocaramidine; Tendor; DEBRISOQUIN SULFATE; Debrisoquin hemisulfate; Debrisoquine sulfate; Isocaramidine sulfate; Debrisoquina [INN-Spanish]; Debrisoquine [INN:BAN]; Debrisoquinum [INN-Latin]; Ro 5-3307/1; Sulfuric acid compound with 3,4-dihydro-2(1H)-isoquinolinecarboximidamide (1:1); 1,2,3, 4-Tetrahydro-isoquinoline-2-carboxamidine sulfate; 2(1H)-Isoquinolinecarboxamidine, 3,4-dihydro-(7CI,8CI); 2(1H)-Isoquinolinecarboxamidine, 3,4-dihydro-, sulfate (2:1); 2(1H)-Isoquinolinecarboximidamide, 3,4-dihydro-, sulfate (2:1); 2-Amidino-1,2,3,4-tetrahydroisoquinoline; 3,4-Dihydro-2(1H)-isoquinolinecarboxamidine; 3,4-Dihydro-2(1H)-isoquinolinecarboxamidine sulfate (2:1); 3,4-Dihydro-2(1H)-isoquinolinecarboximidamide; 3,4-Dihydro-2(1H;)-isoquinoline carboxamidine sulfate; 3,4-dihydro-1H-isoquinoline-2-carboximidamide; 3,4-dihydroisoquinoline-2(1H)-carboximidamide
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Hypertension [ICD11:BA00] | Approved | [1] | |||
| Therapeutic Class |
Antihypertensive Agents
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C10H13N3
|
|||||
| Canonical SMILES |
C1CN(CC2=CC=CC=C21)C(=N)N
|
|||||
| InChI |
InChI=1S/C10H13N3/c11-10(12)13-6-5-8-3-1-2-4-9(8)7-13/h1-4H,5-7H2,(H3,11,12)
|
|||||
| InChIKey |
JWPGJSVJDAJRLW-UHFFFAOYSA-N
|
|||||
| CAS Number |
CAS 1131-64-2
|
|||||
| Pharmaceutical Properties | Molecular Weight | 175.23 | Topological Polar Surface Area | 53.1 | ||
| Heavy Atom Count | 13 | Rotatable Bond Count | 1 | |||
| Hydrogen Bond Donor Count | 2 | Hydrogen Bond Acceptor Count | 1 | |||
| XLogP |
0.8
|
|||||
| PubChem CID | ||||||
| PubChem SID |
794638
,841242
,5535330
,7846928
,7979030
,8151889
,11112418
,11466400
,11467520
,11486180
,14968163
,29222116
,46507664
,47291325
,47589190
,47885609
,48110673
,48334720
,48415845
,49698461
,50064178
,50100434
,50100435
,50715101
,53787958
,56394850
,57321534
,57872971
,81121137
,88560042
,92308985
,103426282
,104015275
,104302135
,104773785
,125689076
,126525753
,128338031
,131290193
,134337449
,134980804
,137014737
,142987200
,143633555
,160967816
,162776450
,164844863
,170049193
,172913429
,176484158
|
|||||
| ChEBI ID |
ChEBI:34665
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | 1-Oct | Transporter Info | Organic cation transporter 1 | Substrate | [2] | |
| P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [3] | ||
| References | ||||||
| 1 | National Center for Advancing Translational Science-Inxight: drug (X31CDK040E) | |||||
| 2 | The prototypic pharmacogenetic drug debrisoquine is a substrate of the genetically polymorphic organic cation transporter OCT1. Biochem Pharmacol. 2012 May 15;83(10):1427-34. | |||||
| 3 | Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharm Res. 1999 Mar;16(3):408-14. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.